免疫组化检测BAP1缺失预测胸膜间皮瘤患者一线铂类联合培美曲塞化疗生存改善:一项验证研究
研究在丹麦(n=114)和澳大利亚(n=234)两个独立队列中,用组织微阵列免疫组化检测胸膜间皮瘤BAP1状态,评估其与一线铂类联合培美曲塞化疗总生存的关系。BAP1缺失是总生存的独立预测因子,接受该化疗的BAP1缺失患者中位生存显著长于BAP1保留者。
要点
- 丹麦队列BAP1缺失率62%,澳大利亚队列60.3%。
- BAP1缺失是总生存独立预测因子(丹麦HR=2.49,澳大利亚HR=1.48)。
- 一线铂类联合培美曲塞治疗中,BAP1缺失者中位生存显著更长。
核心结论
- BAP1是一线铂类联合培美曲塞化疗后生存的预测生物标志物,也是胸膜间皮瘤的潜在预后标志物。
- 肿瘤BAP1状态是用于治疗分层的有前景的临床工具。
研究设计与样本
- 丹麦奥尔堡胸膜间皮瘤病例(n=114)在组织微阵列上行BAP1染色,从登记处和病历提取人口学、临床和生存数据,排除手术病例。
- 结果在澳大利亚珀斯独立队列(n=234)中验证。
主要发现
- 丹麦和澳大利亚样本中BAP1缺失分别占62%和60.3%。
- 校正组织学亚型、体能状态、年龄、性别和治疗后,BAP1缺失是总生存的独立预测因子(丹麦HR=2.49,p<0.001;澳大利亚HR=1.48,p=0.01)。
- 一线铂类联合培美曲塞治疗患者中,BAP1缺失者中位生存显著长于BAP1保留者(丹麦20.1个月 vs 7.3个月,p<0.001;澳大利亚19.6个月 vs 11.1个月,p<0.01)。
- BAP1保留且接受铂类联合培美曲塞治疗者的生存与接受最佳支持治疗者相似。
- 接受最佳支持治疗的BAP1缺失者总生存更高,但仅在澳大利亚队列中显著(16.8个月 vs 8.3个月,p<0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemetrexed therapy. METHODS: PM cases (n = 114) from Aalborg, Denmark, were stained for BAP1 on tissue microarrays. Demographic, clinical, and survival data were extracted from registries and medical records. Surgical cases were excluded. BAP1 status was associated with overall survival (OS) by Cox regression and Kaplan-Meier methods. Results were validated in an independent cohort from Perth, Australia (n = 234). RESULTS: BAP1 loss was found in 62% and 60.3% of all Danish and Australian samples, respectively. BAP1 loss was an independent predictor of OS in multivariate analyses corrected for histological subtype, performance status, age, sex, and treatment (hazard ratio = 2.49, p < 0.001, and 1.48, p = 0.01, respectively). First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01). Survival in patients with BAP1 retained and treated with platinum and pemetrexed was similar as in those with best supportive care. There was a higher OS in patients with best supportive care with BAP1 loss, but it was significant only in the Australian cohort (16.8 versus 8.3 mo, p < 0.01). CONCLUSIONS: BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM. BAP1 in tumor is a promising clinical tool for treatment stratification.
引用
- Louw A, Panou V, Szejniuk WM, et al. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. J Thorac Oncol. 2022. PMID: 35489694. doi:10.1016/j.jtho.2022.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。